RaQualia Pharma Inc.JP:4579
| Dec 31,
2012 | Dec 31,
2013 | Dec 31,
2014 | Dec 31,
2015 | Dec 31,
2016 | Dec 31,
2017 | Dec 31,
2018 | Dec 31,
2019 | Dec 31,
2020 | Dec 31,
2021 | Dec 31,
2022 | Dec 31,
2023 |
|---|
| Business revenue | 29 | 228 | 154 | 146 | 705 | 1,419 | 745 | 1,703 | 1,107 | 2,776 | 2,918 | 1,901 |
|---|
| Cost of business revenue | - | 0 | 3 | - | 118 | 150 | 89 | 263 | 138 | 321 | 232 | 245 |
|---|
| Research and development expenses | 1,804 | 1,518 | 1,516 | 1,302 | 796 | 849 | 1,075 | 864 | 932 | 1,127 | 1,249 | 1,373 |
|---|
| Other selling, general and administrative expenses | 862 | 848 | 819 | 708 | 551 | 572 | 656 | 592 | 523 | 620 | 572 | 621 |
|---|
| Business expenses | 2,666 | 2,366 | 2,337 | 2,010 | 1,465 | 1,570 | 1,820 | 1,719 | 1,593 | 2,068 | 2,052 | 2,239 |
|---|
| Operating profit (loss) | -2,637 | -2,138 | -2,184 | -1,865 | -760 | -150 | -1,075 | -16 | -486 | 708 | 866 | -337 |
|---|
| Interest income | 4 | 1 | 34 | 4 | 13 | 4 | 9 | 9 | 4 | 2 | 1 | 3 |
|---|
| Interest on securities | 2 | - | - | 78 | 52 | 35 | 32 | 35 | 28 | 21 | 13 | 6 |
|---|
| Foreign exchange gains | - | 55 | 27 | 14 | - | 1 | - | - | - | 146 | 44 | 52 |
|---|
| Gain on valuation of derivatives | - | - | - | - | - | - | - | - | - | - | 14 | - |
|---|
| Gain on valuation of compound financial instruments | - | - | 20 | - | 8 | - | - | 4 | 1 | 0 | - | 3 |
|---|
| Subsidy income | - | - | - | - | 20 | 44 | 1 | 0 | 2 | 6 | - | 3 |
|---|
| Other | 22 | 10 | 6 | 1 | 2 | 1 | 3 | 1 | 1 | 3 | 6 | 21 |
|---|
| Non-operating income | 28 | 327 | 87 | 99 | 94 | 85 | 45 | 49 | 35 | 177 | 77 | 88 |
|---|
| Interest expenses | - | - | - | - | - | - | - | - | 0 | 1 | 6 | 7 |
|---|
| Commitment fees | - | - | - | - | - | - | - | - | - | - | 6 | 9 |
|---|
| Share issuance costs | - | 8 | 7 | 6 | - | 13 | 1 | 12 | 0 | 0 | 16 | 4 |
|---|
| Loss on valuation of derivatives | - | - | - | - | - | - | - | - | - | 10 | - | 25 |
|---|
| Loss on valuation of derivatives | - | - | - | - | - | - | - | - | - | 10 | - | 25 |
|---|
| Loss on valuation of compound financial instruments | - | - | - | 21 | - | 2 | 1 | - | - | - | 11 | - |
|---|
| Loss on valuation of compound financial instruments | - | - | - | 21 | - | 2 | 1 | - | - | - | 11 | - |
|---|
| Share issuance costs | - | 8 | 7 | 6 | - | 13 | 1 | 12 | 0 | 0 | 16 | 4 |
|---|
| Other | 17 | 1 | - | - | - | 0 | - | - | - | - | - | 0 |
|---|
| Non-operating expenses | 282 | 9 | 20 | 29 | 55 | 15 | 35 | 12 | 76 | 21 | 39 | 44 |
|---|
| Ordinary profit (loss) | -2,891 | -1,820 | -2,116 | -1,795 | -721 | -81 | -1,065 | 22 | -528 | 864 | 904 | -293 |
|---|
| Gain on sale of investment securities | - | 801 | 1,544 | 66 | - | 18 | 5 | 6 | 8 | 14 | 10 | - |
|---|
| Gain on redemption of investment securities | - | - | - | - | - | - | - | - | - | 2 | 4 | - |
|---|
| Extraordinary income | - | 801 | 1,549 | 66 | - | 21 | 5 | 6 | 9 | 17 | 14 | - |
|---|
| Loss on redemption of investment securities | - | - | - | 6 | 2 | - | 18 | - | 7 | - | - | 1 |
|---|
| Loss on valuation of investment securities | - | - | - | - | - | - | - | - | - | - | 50 | - |
|---|
| Retirement benefits for directors (and other officers) | - | - | - | - | - | - | - | - | - | - | 18 | - |
|---|
| Extraordinary losses | 10 | 83 | 65 | 119 | 2 | 0 | 18 | - | 9 | - | 68 | 1 |
|---|
| Profit (loss) before income taxes | -2,902 | -1,102 | -632 | -1,848 | -723 | -60 | -1,078 | 27 | -528 | 881 | 851 | -294 |
|---|
| Income taxes - current | 4 | 6 | 7 | 6 | 1 | 3 | 27 | 20 | 84 | 122 | 129 | 94 |
|---|
| Income taxes - deferred | - | - | - | - | 4 | -5 | -0 | 2 | -5 | 3 | -1 | -64 |
|---|
| Income taxes | - | - | - | 6 | 5 | -2 | 26 | 22 | 79 | 125 | 128 | 30 |
|---|
| Profit (loss) | - | - | - | -1,854 | -728 | -58 | -1,105 | 5 | -607 | 756 | 723 | -324 |
|---|
| Profit (loss) attributable to owners of parent | - | - | - | - | - | -58 | -1,105 | 5 | -607 | 756 | 723 | -324 |
|---|